

## Special Issue

# Prostate Cancer Targeted Therapy: Highlighting Advances in Precision Medicine and Rational Combination Approaches

### Message from the Guest Editor

The clinical landscape for advanced prostate cancer is rapidly changing. The field is quickly moving toward a targeted paradigm, where individualized patient tumor characteristics will guide treatment decisions, leading to tailored, improved outcomes. In this Special Issue, we seek to highlight cutting-edge research advances working to promote and incorporate the use of targeted and rational approaches for advanced and intractable prostate cancer. Studies detailing basic, translational, and clinical work to advance targeted and rational combination strategies are highly encouraged. Work to develop, understand, and incorporate clinical biomarkers to better stratify patients for treatment are also welcomed. Additionally, reviews summarizing different aspects of targeted therapy for prostate cancer and current clinical findings and perspectives will be warmly accepted for review. We express our warmest thanks for considering this opportunity to highlight the latest research in treating advanced prostate cancer.

---

### Guest Editor

Dr. Alan P. Lombard

1. Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA
2. Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95616, USA

---

### Deadline for manuscript submissions

closed (30 June 2026)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/199529](https://mdpi.com/si/199529)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).